Sugi Predict

Sugi Predict / Compounds / SCHEMBL478316

SCHEMBL478316

SCHEMBL478316

CC(C)(C)C(NC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 1/20 0.54
▸ CTRB1 P17538 2/20 0.54
▸ ATM Q13315 2/20 0.53
▸ ELANE P08246 2/20 0.53
▸ CTSL P07711 5/20 0.53
▸ CTSS P25774 5/20 0.53
▸ CTSB P07858 4/20 0.53
▸ CTSK P43235 5/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ PRTN3 P24158 1/20 0.50
▸ CTSD P07339 1/20 0.49
▸ ITGB3 P05106 1/20 0.49
▸ ITGA2B P08514 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL738204 1.00 SYK (0.54) SYKCTRB1ATMELANECTSL
SCHEMBL10257423 0.94 CTSD (0.53) SYKCTRB1ATMELANECTSL
SCHEMBL12195056 0.94 CTSD (0.53) SYKCTRB1ATMELANECTSL
SCHEMBL16328282 0.90 ALDH1A1 (0.54) SYKCTRB1ATMELANECTSL
SCHEMBL8667196 0.90 TRPM8 (0.54) SYKCTRB1ATMELANECTSL
SCHEMBL9800760 0.90 SYK (0.53) SYKCTRB1ATMELANECTSL
SCHEMBL12493693 0.88 CTRB1 (0.55) SYKCTRB1ATMELANECTSL
SCHEMBL15889351 0.88 SYK (0.52) SYKCTRB1ATMELANECTSL
SCHEMBL7333862 0.88 CTRB1 (0.55) SYKCTRB1ATMELANECTSL
SCHEMBL15338732 0.88 SYK (0.52) SYKCTRB1ATMELANECTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138988-A1 Spiropyrrolidine Derived Antiviral Agents ENANTA PHARMACEUTICALS INC (US) 2026-05-21 — — US disclosed
US-12479854-B2 Spiropyrrolidine derived antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2025-11-25 — — US disclosed
WO-2025224463-A1 DESMURAMYLPEPTIDE ANALOGUE MONOESTER Imhotex Limited (GB) 2025-10-30 — — WO disclosed
US-20250122153-A1 Protease Inhibitors as Antivirals ACEA Therapeutics, Inc. (US) 2025-04-17 — — US disclosed
US-20250059171-A1 ANTIVIRAL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-02-20 — — US disclosed
WO-2025011610-A1 AMIDE DERIVATIVE, AND COMPOSITION AND USE THEREOF 深圳市塔吉瑞生物医药有限公司 2025-01-16 — — WO disclosed
EP-4444711-A1 ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-10-16 — — EP disclosed
EP-4376834-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS Enanta Pharmaceuticals, Inc. (US) 2024-06-05 — — EP disclosed
US-11987554-B2 Protease inhibitors as antivirals VIVASOR, INC. (US) 2024-05-21 — — US disclosed
CN-118043045-A Novel spiropyrrolidine derived antiviral drugs 英安塔制药有限公司 2024-05-14 — — CN disclosed
US-20030119899-A1 Process and intermediates for making substituted aspartic acid acetals VERTEX PHARMACEUTICALS INCORPORATED 2003-06-26 — — US disclosed
EP-1286989-A2 PRODRUG OF AN ICE INHIBITOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2003-03-05 — — EP disclosed
EP-1278737-A2 PROCESS AND INTERMEDIATES FOR MAKING SUBSTITUTED ASPARTIC ACID ACETALS Vertex Pharmaceuticals Incorporated (US) 2003-01-29 — — EP disclosed
EP-1021405-B1 AZETIDINONE DERIVATIVES FOR THE TREATMENT OF HCMV INFECTIONS BOEHRINGER INGELHEIM CA LTD (CA) 2002-09-25 — — EP disclosed
US-20020013278-A1 Prodrug of an ice inhibitor VERTEX PHARMACEUTICALS INCORPORATED 2002-01-31 — — US disclosed
WO-2001090063-A2 PRODRUG OF AN ICE INHIBITOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2001-11-29 — — WO disclosed
WO-2001081330-A2 PROCESS AND INTERMEDIATES FOR MAKING SUBSTITUTED ASPARTIC ACID ACETALS VERTEX PHARMACEUTICALS INCORPORATED (US) 2001-11-01 — — WO disclosed
US-6242439-B1 Azetidinone derivatives for the treatment of HCMV infections BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2001-06-05 — — US disclosed
US-5304549-A Control or prevention of degenerative joint diseases HOFFMANN-LA ROCHE INC. (US) 1994-04-19 — — US disclosed
EP-0497192-A2 Amino acid derivatives F. HOFFMANN-LA ROCHE AG (CH) 1992-08-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138988-A1 Spiropyrrolidine Derived Antiviral Agents ACE, ACE2, TMPRSS2 SYK 2662/4885CTRB1 101/4885ATM 3005/4885
US-20250122153-A1 Protease Inhibitors as Antivirals ACE, ACE2, TMPRSS15 SYK 4667/4885CTRB1 53/4885ATM 4405/4885
US-11987554-B2 Protease inhibitors as antivirals ACE, ACE2, TMPRSS15 SYK 4667/4885CTRB1 53/4885ATM 4405/4885
US-12479854-B2 Spiropyrrolidine derived antiviral agents ACE, ACE2, PKD1 SYK 2234/4885CTRB1 753/4885ATM 3836/4885
US-20030119899-A1 Process and intermediates for making substituted aspartic acid acetals CASP1, CASP4, CASP2 SYK 2096/4885CTRB1 369/4885ATM 1668/4885
US-20020013278-A1 Prodrug of an ice inhibitor CASP1, MCL1, IL1A SYK 1169/4885CTRB1 1627/4885ATM 2740/4885
US-20250059171-A1 ANTIVIRAL COMPOUNDS ZC3HAV1, ACE, EIF2AK2 SYK 4715/4885CTRB1 223/4885ATM 4706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.